T1	Chemical	7 61	antisense PKA RIalpha and CpG immunomer in combination
T2	Disease	88 103	tumor -targeted
T3	Chemical	88 119	tumor -targeted therapeutics to
T4	Disease	139 140	.
R1	influences	Arg1:T1	Arg2:T2
R2	treats	Arg1:T1	Arg2:T3
R3	treats	Arg1:T1	Arg2:T4
R4	influences	Arg1:T2	Arg2:T1
R5	treats	Arg1:T2	Arg2:T3
R6	treats	Arg1:T2	Arg2:T4
R7	treats	Arg1:T3	Arg2:T4
R8	isAssociatedWith	Arg1:T4	Arg2:T1
R9	isAssociatedWith	Arg1:T4	Arg2:T2
R10	isAssociatedWith	Arg1:T4	Arg2:T3
